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Abstract: Background and objectives: Induction chemotherapy (ICT) before definitive chemoradiation
(CRT) gives high response rates in locally advanced squamous cell carcinoma of the head and neck
(LA-SCCHN). However, pre-ICT gross tumor volume (GTV) for radiotherapy (RT) planning is still
recommended. As 18F-FDG PET/CT has an advantage of biological tumor information comparing
to standard imaging methods, we aimed to evaluate the feasibility of 18F-FDG PET/CT-based
post-ICT GTV delineation for RT planning in LA-SCCHN and to assess the prognostic value of PET
parameters: maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and
total lesion glycolysis (TLG). Methods: 47 LA-SCCHN patients were treated with 3 cycles of ICT
(docetaxel, cisplatin, and 5-fluorouracil) followed by CRT (70 Gy in 35 fractions with weekly cisplatin).
Pre- and post-ICT PET/CT examinations were acquired. Planning CT was co-registered with post-ICT
PET/CT and RT target volumes were contoured according to post-ICT PET. Post-ICT percentage
decrease of SUVmax, MTV and TLG in primary tumor and metastatic regional lymphnodes (LN) was
counted. Loco-regional failure patterns, 3-year progression free (PFS) and overall survival (OS) were
evaluated. Results: 3-year PFS and OS rates for study population were 67% and 61% respectively.
31.9% of patients progressed loco-regionally. All progress was localized in high-to-intermediate
dose (60–70 Gy) RT volumes and none in low dose (50 Gy) volumes. Decrease of SUVmax ≥ 74%
(p = 0.04), MTV ≥ 68% (p = 0.03), TLG ≥ 76% (p = 0.03) in primary tumor, and LN TLG decrease
≥ 74% (p = 0.03) were associated with PFS. Decrease of primary tumor SUVmax ≥ 74% (p = 0.04),
MTV ≥ 69% (p = 0.03), TLG ≥ 74% (p = 0.02) and LN TLG ≥ 73% (p = 0.02) were prognostic factors
for OS. Conclusions: According to our results, 18F-FDG PET/CT-based post-ICT GTV delineation is
feasible strategy without negative impacts on loco-regional control and survival. Percentage decrease
of metabolic PET parameters SUVmax, MTV and TLG has a prognostic value in LA-SCCHN.
Keywords: head and neck cancer; induction chemotherapy; 18F-FDG PET/CT; target volume delineation
1. Introduction
Despite the absence of definitive scientific evidence, induction chemotherapy (ICT) for locally
advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is often used in clinical
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practice [1]. Up to 80–90% of patients with LA-SCCHN respond to cisplatin-based ICT and 20–40% of
them achieve complete response (CR) [2]. Although several studies reported no benefit of ICT in terms
of survival [2–4], it has a role in selected cases if there is likely to be a delay between diagnosis and
starting definitive chemoradiotherapy (CRT) and in organ preservation strategies [5].
The current guidelines suggest that pre-ICT primary site and nodal gross tumor volumes
(GTV) should be used for radiotherapy (RT) planning in cases when ICT is given [6–8].
However, possible superiority of post-ICT over pre-ICT GTV is now under investigation [9,10].
The potential advantages of using post-ICT imaging for target volume delineation include the reduction
of GTV due to tumor shrinkage and the possibility to spare normal tissues. However, it bears a potential
risk of missing partial tumor volume and, in some cases, difficulties in GTV delineation due to
metabolic switch [9,11].
Contrast-enhanced computed tomography and/or magnetic resonance imaging are the standard
methods for evaluating tumor response to ICT, and are mostly used for GTV delineation in LA-SCCHN.
Recent studies report an emerging role of positron emission tomography (PET) with 18Fluorine-labeled
2-fluoro-2-deoxyglucose integrated with computed tomography (18F-FDG PET/CT) in RT planning
for head and neck cancers due to the added biological tumor information. However, there is a lack
of knowledge regarding whether the use of 18F-FDG PET/CT based post-ICT GTV delineation in RT
planning is a feasible approach.
Furthermore, earlier clinical studies demonstrated, that some parameters of 18F-FDG PET/CT may
predict the tumor chemosensitivity and LA-SCCHN patient survival [12–14]. Such 18F-FDG PET/CT
parameters as maximum standard uptake value (SUVmax), metabolic tumor volume (MTV) and total
lesion glycolysis (TLG) have been shown to correlate with LA-SCCHN patient outcome [15–17].
However, the prognostic value of the percentage decrease of these FDG uptake parameters from
baseline to post-ICT is unknown.
The aims of our prospective phase II study were:
1. To evaluate the feasibility of 18F-FDG PET/CT-based post-ICT GTV delineation strategy for
LA-SCCHN RT planning by analyzing patterns of local and/or nodal disease failure after CRT
and assessing progression free survival (PFS) overall survival (OS) and treatment safety;
2. To assess the correlation of post-ICT percentage decrease of three metabolic18F-FDG PET/CT
parameters SUVmax, MTV and TLG in primary tumor and metastatic nodes with the radiological
response to ICT, PFS and OS.
2. Material and Methods
2.1. Study Design and Patient Selection
Between September 2013 and January 2016, patients affected by LA-SCCHN were enrolled in
this phase 2 prospective cohort study. All subjects signed the informed consent form. The study
was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by
the Kaunas Regional Ethics Committee for Biomedical Research (No. BE-2-51; 5 November 2013)
and was registered at www.clinicaltrials.gov (identification no. NCT02047201). All patients have
been validated by the multidisciplinary team for ICT followed by CRT. The eligibility criteria were
as follows: histologically confirmed locally advanced (stage III and IV) head and neck squamous cell
carcinoma, Eastern Cooperative Oncology Group performance status (ECOG) 0 or 1, signed written
informed consent. Patients with a known history of another cancer or suspected metastatic lesions
were excluded.
2.2. Induction Chemotherapy Delivery and Evaluation of Response to ICT
Patients received three cycles of docetaxel, cisplatin, and 5-FU (TPF) ICT consisting of docetaxel
(75 mg/m2) and cisplatin (75 mg/m2) administered as a 1-h infusion on a day 1 and 5-fluorouracil
(5-FU) (750 mg/m2) administered by continuous infusion on days 1–5 [18]. Cycles were administered
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every 3-weeks. The reductions of the docetaxel, cisplatin and 5-FU doses were planned depending on
the individual treatment tolerance and toxicity.
According to post-ICT 18F-FDG PET, patients were classified into: ICT-responders—patients with
≥50% visual tumor volume reduction, and ICT-non-responders—<50% reduction [19,20].
2.3. 18F-FDG PET/CT Examination and Gross Tumor Volume Delineation
Two 18F-FDG PET/CT examinations were performed for each patient, both consisting of
whole-body scan and localized high-resolution head and neck scan. The first imaging was accomplished
prior ICT during initial staging, another one occurred 14± 2 days after the last cycle of ICT for therapeutic
evaluation and CRT planning [7,11,13]. Patient’s preparation for the scan included a low carbohydrate
diet for at least 24 h prior the scan and fasting for more than 6 h. Serum glucose level was measured
on the day of the scan and aimed to be <7 mmol/L. The injected activity of 18F-FDG was 4 MBq/kg of
body weight. After injection patients remained in a quiet room for approximately 60 min. A whole-body
PET/CT scan was acquired from the skull base to the mid-thigh with the patient’s hands above the head.
The examination was started with low-dose CT (120 kV, 100 mA, 3.75 mm section thickness) followed by
PET acquisition (3 min per bed position). Localized high resolution head and neck PET/CT scan was
acquired with the patient positioned with arms along the body. PET acquisition allowed 5 min per bed
position. In addition, post-ICT head and neck scan was performed while patients were positioned on a
radiation therapy planning table in intensity modulated radiation therapy (IMRT) treatment position
with the five-point fixation thermoplastic mask. All 18F-FDGPET/CT studies were performed on GE
Discovery XCT (General Electric Healthcare system, United States of America) scanner. All PET/CT
images were reconstructed with the ordered subset expectation maximization (OSEM) iterative algorithm
using scatter correction with the 5 mm Gaussian filter on 128 × 128 and 256 × 256 matrixes.
All acquired data was transferred to radiotherapy treatment planning system Eclipse (version v8.6)
and registered by aligning the centers of the datasets. Planning CT was rigidly co-registered with
post-ICT 18F-FDGPET/CT for delineation of treatment volumes. The gross tumor volume GTV70
and gross nodal volume GTV60 were manually contoured using a visual interpretation technique on
post-ICT PET images by radiation oncologist in collaboration with an experienced nuclear medicine
physician. Clinical target volumes (CTV) of primary tumor CTV70 obtained by adding 5 mm margin
to GTV70. CTV60 involved GTV70 and GTV60 plus 5 mm margin. The elective CTV (CTV50) included
CTV70, CTV60 and bilateral elective lymph nodes. The margin of 3 mm was added for each CTV
to create the planning target volumes (PTV) PTV70, PTV60 and PTV50 (during RT delivery daily
cone-beam CT (CBCT) for image guidance was used). For high-risk volumes PTV70 and PTV60 the
prescribed doses were 70 Gy and 60 Gy respectively, for PTV50—50 Gy.
Three metabolic parameters (SUVmax, MTV and TLG) were measured in pre-ICT and post-ICT
18F-FDGPET/CT scans for both primary tumor and metastatic regional lymphnodes. Around every
suspicious lesion, the isocontour region of interest centered on the maximum value pixel was drawn
automatically by workstation tools (Metavol software v. 1.4.) generating SUVmax and mean SUV
(SUVmean) of the region. Metabolic tumor volume was drawn manually contouring margin of every
lesion and then segmented semi-automatically in three dimensions. MTV was defined as the summed
volume in cubic centimeters (cm3). TLG was calculated as the product of MTV and SUVmean.
2.4. Chemoradiotherapy
CRT consisted of cisplatin 40 mg/m2 weekly concomitant with conventionally fractionated RT
(2 Gy per once-daily fraction, 5 days a week until the total prescribed dose of 70 Gy will be collected) [21,22].
The cisplatin dose was individually modified according to the level of hematologic toxicity, hepatic and
renal function and the infectious diseases. Non-completion of prescribed radiotherapy dose was
related to individual patient tolerance.
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2.5. End Points
PFS and OS were used as the clinical endpoints to evaluate the feasibility of 18F-FDG
PET/CT-based post-ICT GTV delineation and the prognostic value of the 18F-FDG PET metabolic
parameters. PFS was defined as the time from day 1 of the ICT first cycle until disease progression
or death from any reason. OS was defined as the period from day 1 of the ICT first cycle until death
from any reason. Furthermore, to evaluate the safety of new target volume delineation technique,
treatment toxicity during ICT and CRT was evaluated on a weekly basis according to the National
Cancer Institute Common Toxicity Criteria (NCI CTCAE) v.4.0. Late adverse events related with RT
were assessed every three months after CRT using RTOG (Radiation Therapy Oncology Group)/EORT
(European Organization for Research and Treatment of Cancer) toxicity criteria.
2.6. Analysis of Loco-Regional Failure Patterns
Diagnostic CT or PET/CT documenting recurrence was co-registered with planning CT and
pre-ICT PET/CT using rigid image registration technique. Alternative IMRT treatment plans basing
on pre-ICT PET/CT were also created to investigate the relationship between failure site and primary
PET/CT visual tumor volume. Loco-regional failures were classified depending on the percentage
volume which received in total 95% of the prescribed dose: failures were classified as “in-field” (>95%),
“marginal” (≥20%; ≤95%) and “out-field” (<20%) [23,24]. Mean, minimum and maximum dose and
D95 to the failure volume were estimated.
2.7. Statistics
Means of pre-ICT, post-ICT and the percentage decrease of SUVmax, MTV and TLG were compared
between ICT-responder versus ICT-non-responder groups using Student’s t-test. ROC curve analysis
was applied to identify the best discriminating cut-off values for SUVmax, MTV, and TLG to predict PFS
and OS. Appropriate cut-off was defined as the point on the curve nearest to the upper left corner of the
receiver operating characteristics (ROC) graph. The area under the curve (AUC) was used to evaluate
the accuracy of the metabolic parameters as a prognostic factor. The Kaplan—Meier method was
applied to estimate PFS and OS. The Cox regression model was applied for the estimation of the hazard
ratio (HR); and for the multivariate analysis using a forward selection. Log-rank test (Mantel–Cox)
was used to compare survival distributions. All tests were two-sided, and the significance threshold
was set at p < 0.05. All statistical analyses were performed using IBM SPSS 22.0 (Statistical Package for
Social Sciences 22.0 for Windows) statistical software.
3. Results
3.1. Patient Characteristics
In total 53 patients (50 males and 3 females) with mean age at diagnosis of 55.8 ± 8.9 (range 30–71)
years were enrolled in this study. As demonstrated in flow diagram of study participants (Figure 1),
47 patients completed ICT and CRT and were eligible for further analysis. 21 (44.7%) of analyzed patients
had primary hypopharyngeal carcinoma and 26 (55.3%)—oropharyngeal carcinoma (all cases negative
for human papillomavirus). Patient characteristics at the time of diagnosis are listed in Table 1.
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cisplatin, and 5-fluorouracil (5-FU); IMRT—intensity modulated radiation therapy; CRT—
chemoradiotherapy. 
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Male 45 (95.7) 
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ECOG, n (%)  
0 30 (63.8) 
1 17 (36.2) 
Primary tumor site, n (%)  
Oropharynx 26 (55.3) 
Hypopharynx 21 (44.7) 
Tumor status (T), n (%)  
T1 0 
T2 14 (29.8) 
T3 9 (19.1) 
T4 24 (51.1) 
Lymph node status (N), n (%)  
N0 3 (6.4) 
N1 9 (19.1) 
Figure 1. Flow iagram of study participants. TPF—induction chemotherapy c nsisting of
docetaxe , cisplatin, and 5-fluorouracil (5-FU); IMRT—intensi y mo ulated radiation therapy;
CRT—chemoradiotherapy.
Table 1. Baseline patient a or characteristics.
Characteristics Value
Age, median (range), years 55.5 (30–71)
Sex, n (%)
Male 45 (95.7)
Female 2 (4.3)
ECOG, n (%)
0 30 (63.8)
1 17 (36.2)
Primary tumor site, n (%)
Oropharynx 26 (55.3)
Hypopharynx 21 (44.7)
Tumor status (T), n (%)
T1 0
T2 14 (29.8)
T3 9 (1 .1)
T4 24 (51.1)
Lymph node status (N), n (%)
N0 3 (6.4)
N1 9 (1 .1)
N2 32 (68.1)
N3 3 (6.4)
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Table 1. Cont.
Characteristics Value
Tumor stage, n (%)
III 7 (14.9)
IV 40 (85.1)
Histological grade, n (%)
G1 1 (2.1)
G2 27 (57.4)
G3 19 (40.5)
G4 0
ECOG—Eastern Cooperative Oncology Group performance status.
3.2. Clinical Outcome of 18F-FDG PET/CT-Based Post-ICT GTV Delineation Strategy
Median follow-up of patients was 36.4 months (range: 9.7–57.2). 3-year PFS and OS rates for all study
population were 67% and 61% respectively. According to post-ICT 18F-FDG PET/CT, 10 (21.3%) patients
were ICT-non-responders and 37 (78.7%)—ICT-responders (a representative case of ICT-responder is
demonstrated in Figure 2). The 3-year PFS for ICT-non-responders was 20%, comparing with 84% for
ICT-responders (Hazard ratio (HR) = 6.5, 95% CI 2.33–18.7; p = 0.001) (Figure 3). The 3-year OS for
ICT-non-responders was 16% vs. 78% for ICT-responders (HR = 5.47, 95% CI 2.33–12.83; p = 0.001)
(Figure 4). The median PFS and OS were not reached.
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3.3. Patterns of Loco-Regional Failures
Loco-regional disease failure occurred in 15 patients (31.9%) (7 in ICT-responder group and 8 in
ICT-non-responder group). For 5 patients (10.6%) it was allocated at the primary tumor site, 7 patients
(14.9%) had local control but regional failure and 3 patients (6.4%) had both primary and nodal failure.
Every single recurrent lesion was analyzed separately and in total 32 locoregional recurrent lesions of
15 patients were analyzed. Relative to the percentage target volume that received 95% of the prescribed
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dose for specific PTV, a total of 19 (59.3%) failures were classified as in-field, 7 (21.9%) failures were
defined as marginal and 6 (18.8%) failures as out-field. The average mean (± standard deviation (SD)),
minimum, maximum dose and dose to 95% of planning target volume (D95) did not differ significantly
among in-field, marginal and out-field recurrence sites (Table 2).
The primary tumor persisted or recurred at the site of high-dose GTV (GTV70) and high-dose CTV
(CTV70) in 7 (87.5%) cases, and 1 (12.5%) case occurred in high-dose PTV (PTV70). The failure of LN
observed in intermediate-dose GTV (GTV60) and intermediate-dose CTV (CTV60) in 21 (87.5%) cases,
and 3 (12.5%) cases in intermediate-dose PTV (PTV60). No failures were observed in prophylactic dose
PTV (PTV50). In high dose PTV70 volumes, significantly lower dose coverage was observed (Table 2).
Table 2. Sites of loco-regional failures and RT doses in post-ICT PET/CT based IMRT plans.
Characteristic Failures, n (%) Dose, Average± SD
Type Mean Dose Minimum Dose Maximum Dose D95
Primary site
In-field 5 (62.5) 67 ± 4.3 65 ± 3.5 71 ± 2.9 67.64 ± 2.6
Marginal 1 (12.5) 69.9 64.41 71.7 68.4
Out-field 2 (25.0) 58.5 ± 14.85 49.5 ± 21 71.7 ± 0.1 51.71 ± 24
p value 0.41 0.25 0.9 0.2
LN
In-field 14 (58.3) 64.4 ± 3.15 61.93 ± 3.40 67.03 ± 2.96 62.8 ± 3.40
Marginal 7 (29.2) 62.3 ± 1.49 55.8 ± 9.60 66 ± 2.65 59.6 ± 8.36
Out-field 3 (12.5) 59.4 ± 7.36 59.47 ± 7.40 68.1 ± 2.98 58.9 ± 8.13
p value 0.14 0.08 0.8 0.37
Primary site
GTV * 5 (62.5) 66.9 ± 4.26 65 ± 3.50 71 ± 2.90 67.64 ± 2.60
CTV * 2 (25.0) 69.44 ± 0.60 64.3 ± 0.15 71.84 ± 0.23 68.5 ± 0.24
PTV * 1 (12.5) 48 34.7 71.7 34.7
p value 0.013 0.001 0.8 0.001
LN
GTV ** 14 (58.3) 64.4 ± 3.15 61.93 ± 3.40 67.03 ± 2.96 62.8 ± 3.40
CTV ** 6 (25.0) 61.84 ± 0.90 54.92 ± 10.20 65.93 ± 2.90 59 ± 9.01
PTV ** 4 (16.7) 60.9 ± 6.64 56.6 ± 8.70 67.65 ± 2.60 59.9 ± 6.94
p value 0.15 0.08 0.91 0.37
* high-dose (70 Gy) GTV, CTV and PTV of primary site failures; ** intermediate-dose (60 Gy) GTV, CTV and PTV of
lymph nodes failures; LN—regional lymph nodes.
Furthermore, patterns of locoregional failure in alternative virtual IMRT plans based on pre-ICT
PET/CT images were analyzed. Primary tumor site failures were classified as in-field in 6 (75%) cases,
marginal in 2 (25%) cases and none as out-field. As for LN failures: 18 (75%) in-field, 4 (16.7%) marginal
and 2 (8.3%) out-field. Evaluating radiation target volumes, 6 recurrences of primary tumor were in
GTV70 and 2 in CTV70. The failure of LN recurred at the site of intermediate-dose GTV60 in 18 cases,
3 cases in CTV60 and 3 cases in PTV60. No failures were observed in prophylactic dose PTV (PTV50).
In intermediate-dose PTV60 volumes, significantly lower PTV dose coverage was observed (Table 3).
There were no significant differences between pre-ICT and post-ICT IMRT plans according to failure
localization, D95, mean, minimum and maximum dose.
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Table 3. Sites of loco-regional failures and RT doses in pre-ICT PET/CT based IMRT plans.
Characteristic Failures, n (%) Doses Average (± SD)
Type Mean Dose Minimum Dose Maximum Dose D95
Primary site
In-field 6 (75) 67.2 ± 3.9 64.8 ± 3.4 71.1 ± 2.6 66.3 ± 4.6
Marginal 2 (25) 63.7 ± 8.9 60.1 ± 6.2 71.2 ± 0.6 68 ± 0.1
Out-field - - - - -
p value 0.42 0.18 0.9 0.17
LN
In-field 18 (75) 63.7 ± 3.1 59.7 ± 7.1 66.8 ± 3.1 61.3 ± 5.9
Marginal 4 (16.7) 61.8 ± 6.1 56.7 ± 8.6 67.3 ± 2.8 63.3 ± 7.1
Out-field 2 (8.3) 64.1 ± 1.5 60.9 ± 0.2 66.35 ± 0.5 63.9 ± 1.4
p value 0.217 0.69 0.92 0.76
Primary site
GTV * 6 (75) 67.2 ± 3.9 64.8 ± 3.1 71.1 ± 2.6 67.8 ± 2.3
CTV * 2 (25) 63.6 ± 8.9 60.1 ± 6.2 71.2 ± 0.6 64.4 ± 8.4
PTV * - - - - -
p value 0.42 0.18 0.76 0.17
LN
GTV ** 18 (75) 63.97 ± 2.9 61.6 ± 3.1 66.7 ± 2.8 63.03 ± 3
CTV ** 3(12.5) 60.6 ± 6.9 52.3 ± 8.7 67.35 ± 3.8 56.62 ± 6.3
PTV ** 3 (12.5) 63.03 ± 2.1 52.4 ± 11.8 68.1 ± 3.0 54.53 ± 12.8
p value 0.07 0.013 0.67 0.04
* high-dose (70 Gy) GTV, CTV and PTV of primary site failures; ** intermediate-dose (60 Gy) GTV, CTV and PTV of
lymph nodes failures; LN—regional lymph nodes.
3.4. Toxicities
During CRT the rates of grade 3–4 dermatitis, mucositis, anemia, leukopenia and thrombocytopenia
were 27.6%, 21.2%, 6.4%, 6.4% and 6.4%, respectively. No grade 3 or 4 xerostomia or body-weight
loss were observed. The incidence of grade 3–4 late toxicities was: 1 (2.1%) patient developed
osteoradionecrosis, 1 (2.1%) developed trismus, 2 (4.3%) dysphagia and 1 (2.1%) bleeding.
3.5. ROC Curve Analysis, AUC and Cut-Off Values of the Metabolic Parameters
The mean of SUVmax percentage decrease of the primary lesions after ICT was 58.9 ± 24.7%
and the mean of MTV and TLG percentage decrease of the primary lesions were 63.4 ± 33.6% and
66.3 ± 41.2% respectively. The mean of SUVmax, MTV and TLG percentage decrease of metastatic LN
were 38.5 ± 32.8%, 38.5 ± 32.8% and 64.9 ± 34.6% respectively. The abilities of the SUVmax, MTV,
and TLG post-ICT percentage decrease values to predict PFS and OS were calculated by ROC curves.
AUC of the tested parameters, their optimal cut-off values for PFS and OS are demonstrated in Table 4.
3.6. Prognostic Value of the Metabolic Parameters
Associations of three metabolic 18F-FDG PET/CT parameters SUVmax, MTV and TLG in primary
tumor and metastatic nodes with post-ICT tumor volume reduction are demonstrated in the Tables 5
and 6. Tumor response was associated with primary tumor parameters: pre-ICT MTV (p < 0.001)
and TLG (p = 0.02); post-ICT SUVmax (p = 0.004), MTV (p < 0.001) and TLG (p < 0.001); percentage
decrease of SUVmax (p = 0.027) and MTV (p = 0.001). Tumor response was also statistically significantly
linked with metastatic LN parameters: pre-ICT MTV (p < 0.001) and TLG (p < 0.001); post-ICT MTV
(p = 0.006) and TLG (p < 0.001). Percentage decrease of LN metabolic parameters was not associated
with tumor response.
According to the univariate Cox regression analysis (Tables 7 and 8), percentage decrease of
primary tumor SUVmax ≥ 74%, MTV≥ 68%, TLG≥ 76%, metastatic LN SUVmax ≥ 68% and TLG≥ 74%
and lymphnode status N were significant prognostic factors for PFS. Percentage decrease of primary
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tumour SUVmax ≥ 74%, MTV ≥ 69%, TLG ≥ 74%, metastatic LN SUVmax ≥ 69% and TLG ≥ 73% and
lymphnode status N were significant prognostic factors for OS.
In multivariate analysis (Tables 7 and 8) primary tumor SUVmax decrease ≥ 74% (HR = 1.4;
95% CI 1.2–9.3; p = 0.04), primary tumor MTV decrease ≥68% (HR = 1.9; 95% CI 1.3–11.5; p = 0.03),
primary tumor TLG decrease ≥ 76% (HR = 3.7; 95% CI 1.2–9.3; p = 0.03), LN TLG decrease ≥ 74%
(HR = 2.9; 95% CI 1.3–6.9; p = 0.03) and N stage (HR = 2.8; 95% CI 1.7–16.3; p = 0.02) remained
significantly associated with PFS. Moreover, ≥74% decrease in primary tumor SUVmax (HR = 1.2;
95% CI 1.1–5.8; p = 0.04), ≥69% decrease in primary tumor MTV (HR = 1.8; 95% CI 1.3–6.7; p = 0.03),
≥74% decrease in primary tumor TLG (HR = 3.1; 95% CI 1.4–17.6; p = 0.02), ≥73% decrease in LN
TLG (HR = 2.6; 95% CI 1.4–6.2; p = 0.02) and N stage (HR = 2.2; 95% CI 1.4–8.7; p = 0.02) remained
independent prognostic factors for OS.
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Table 4. AUC and cut-off values of metabolic parameters.
Parameter
PFS OS
AUC OptimalCut-Off, % Sensitivity/Specificity, % AUC
Optimal
Cut-Off, % Sensitivity/Specificity, %
Primary tumor
percentage
decrease of:
SUVmax 0.79 74 68/88 0.70 74 69/67
MTV 0.83 68 71/88 0.76 69 76/78
TLG 0.78 76 74/88 0.78 74 74/81
Metastatic LN
percentage
decrease of:
SUVmax 0.72 68 68/89 0.68 69 69/67
MTV 0.58 - - 0.50 - -
TLG 0.79 74 62/87 0.71 73 72/69
AUC—area under the curve; LN—regional lymphnodes; PFS—progression-free survival; OS—overall survival; “-“—no optimal cut off point.
Table 5. Associations of 18F-FDG PET/CT metabolic parameters with tumor response to ICT in primary tumor.
Parameter of the Primary Tumor Total Mean± SD ICT-Responders Mean± SD ICT-Non-Responders Mean± SD p Value
Pre-ICT SUVmax 17.9 ± 5.8 17.6 ± 1.1 18.9 ± 1.4 0.910
MTV 34.6 ± 26.6 27.7 ± 3.3 52.7 ± 9.7 <0.001
TLG 232.3 ± 209.2 178 ± 24.1 372 ± 77.5 0.020
Post-ICT SUVmax 7.2 ± 5.02 3.1 ± 0.9 5.9 ± 3.5 0.004
MTV 11.8 ± 15.7 6.04 ± 6.9 27.04 ± 21.7 <0.001
TLG 60.05 ± 91.11 27.2 ± 56.2 146 ± 110 <0.001
Percentage decrease (%) SUVmax 58.9 ± 24.7 68.3 ± 2.7 34.6 ± 7.2 0.027
MTV 63.4 ± 33.6 74.4 ± 3.2 34.7 ± 12.2 0.001
TLG 66.3 ± 41.2 68.3 ± 2.7 34.6 ± 7.2 0.950
SUVmax—maximum standard uptake value; MTV—metabolic tumor volume; TLG—total lesion glycolysis; SD—standard deviation; ICT—induction chemotherapy.
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Table 6. Associations of 18F-FDG PET/CT metabolic parameters with tumor response to ICT in metastatic LN.
Parameter of the Metastatic LN Total Mean± SD ICT-Responders Mean± SD ICT-Non-Responders Mean± SD p Value
Pre-ICT SUVmax 13.02 ± 6.4 12.4 ± 1.1 14.9 ± 1.9 0.820
MTV 19.3 ± 28.2 12.1 ± 2.4 40.9 ± 13 <0.001
TLG 140.3 ± 234.9 77.1 ± 15 330.2 ± 109.7 <0.001
Post-ICT SUVmax 7.5 ± 5.7 3.3 ± 1.8 5.5 ± 2.5 0.115
MTV 50.5 ± 129.2 24.1 ± 58.5 129.54 ± 227.2 0.006
TLG 60.05 ± 91.11 27.2 ± 56.2 146 ± 110 <0.001
Percentage decrease (%) SUVmax 38.5 ± 32.8 44 ± 5.7 22.2 ± 7.3 0.340
MTV 38.5 ± 32.8 62 ± 4.7 39.1 ± 12.2 0.211
TLG 64.9 ± 34.6 72.3 ± 4.3 42.9 ± 13.4 0.090
SUVmax—maximum standard uptake value; MTV—metabolic tumor volume; TLG—total lesion glycolysis; SD—standard deviation; LN—regional lymphnodes.
Table 7. Univariate and multivariate Cox proportional hazards regression analysis for PFS.
Parameter Cut-Off Value
Univariate Multivariate
HR 95%CI p Value HR 95%CI p Value
Primary tumor
percentage decrease of:
SUVmax <74 vs. ≥74% 1.3 1.1–2.1 0.04 1.4 1.2–9.3 0.04
MTV <68 vs. ≥68% 1.5 1.3–9.5 0.01 1.9 1.3–11.5 0.03
TLG <76 vs. ≥76% 4.9 1.8–13.6 0.002 3.7 1.2–9.3 0.03
Metastatic LN percentage
decrease of:
SUVmax <68 vs. ≥68% 1.2 1.2–2.2 0.04 0.7 0.2–2.7 NS
MTV * - - - - - -
TLG <74 vs. ≥74% 1.6 1.5–4.2 0.03 2.9 1.3–6.9 0.03
Tumor status (T) T2-3 vs. T4 0.9 0.5–2.3 NS - - -
Lymphnode status (N) N0-1 vs. N2-3 3.4 1.6–7.8 0.01 2.8 1.7–16.3 0.02
Tumor site Oropharynx vs. hypopharynx 0.7 0.3–1.7 NS - - -
Histological grade G1-2 vs. G3 0.3 0.24–1.4 NS - - -
SUVmax—maximum standard uptake value; MTV—metabolic tumor volume; TLG—total lesion glycolysis; LN—regional lymphnodes; * no optimal cut-off value; NS—not significant.
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Table 8. Univariate and multivariate Cox proportional hazards regression analysis for OS.
Parameter Cut-Off Value
Univariate Multivariate
HR 95%CI p Value HR 95%CI p Value
Primary tumor
percentage decrease of:
SUVmax <74 vs. ≥74% 2.5 1.3–7.9 0.03 1.2 1.1–5.8 0.04
MTV <69 vs. ≥69% 1.8 1.3–5.4 0.04 1.8 1.3–6.7 0.03
TLG <74 vs. ≥74% 3.2 1.3–7.7 0.01 3.1 1.4–17.6 0.02
Metastatic LN percentage
decrease of:
SUVmax <69 vs. ≥69% 1.4 1.2–5.5 0.03 0.8 0.7–2.3 NS
MTV * - - - - - -
TLG <73 vs. ≥73% 2.2 1.4–11.5 0.02 2.6 1.4–6.2 0.02
Tumor status (T) T2-3 vs. T4 0.8 0.6–3.4 NS - - -
Lymphnode status (N) N0-1 vs. N2-3 3.9 1.3–9.4 0.03 2.2 1.4–8.7 0.02
Tumor site Oropharynx vs. hypopharynx 0.7 0.3–1.7 NS - - -
Histological grade G1-2 vs. G3 0.6 0.2–1.4 NS - - -
SUVmax—maximum standard uptake value; MTV—metabolic tumor volume; TLG—total lesion glycolysis; LN—regional lymphnodes; *—no optimal cut-off value.
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4. Discussion
Our study is the first to investigate the feasibility of target volume delineation based on post-ICT
18F-FDG PET/CT images for LA-SCCHN IMRT planning. The rationale for this approach is the
potential reduction of GTV after ICT leading to mitigation of RT toxicities by sparing normal tissues.
Several authors in their publications have discussed post-ICT imaging-based target volume delineation
strategy [6,8,9,25]. However, due to the lack of supportive data they still recommend the use of
pre-induction primary tumour and nodal GTVs but further clinical research is needed.
Survival data from our study cannot be directly compared with the results of other authors because
there are no completed clinical trials analysing post-ICT PET/CT based RT planning. For indirect
comparison patients’ outcomes of several clinical studies, where ICT plus CRT approach was used
for LA-SCCHN treatment are presented in Table 9. One of the earliest published studies analysing
LA-SCCHN patients treated with ICT (TPF) plus CRT was TAX-324 [26]. In this study 3-year PFS
and OS rates were 50% and 62% respectively. In the PARADIGM study published by Haddad et al.,
patients in ICT arm received 3 cycles of TPF plus CRT with weekly carboplatin, 67% of patients
were progress free and 73% were alive in 3 years after treatment [4]. Takacsi-Nagy et al. in phase
II clinical trial involving 66 LA-SCCHN patients demonstrated that after 2 cycles of TPF followed
by CRT (total dose of 70 Gy in 7 weeks with 3 concurrent cycles of cisplatin on days 1, 22 and
43 of radiotherapy) 3-year PFS rate was 41% and OS rate - 43% [27]. Ghi et al. analysed 208 patients
randomised for either CRT with cisplatin (n = 129) or radiotherapy with cetuximab (n = 79) after
initial 3 cycles of TPF [28]. 3-year PFS and OS rates were 47% and 57.5% respectively. In our study,
involving 47 patients treated with 3 cycles of TPF plus CRT (70 Gy in 7 weeks with weekly cisplatin
40 mg/m2), we demonstrated 3-year PFS rates of 67% and 3-year OS rates of 61%. Summarizing the
data, 3-year PFS and OS rates in our study were non-inferior comparing to survival results in studies
with the standard treatment approach.
Table 9. Patient survival data in previous studies with ICT plus CRT approach and in our study.
Study Eligibility Patients Study Design 3-YearOS Rates
3-Year PFS
Rates
Lorch et al. [26] Stage III-IV 501 TPFx3, SRT+CBP weekly vs.CP/5-Fu, SRT+CBP weekly 62% 50%
Haddad et al. [4] Stage III-IV 145 TPFx3, SRT+CBP weekly vs.HRT+CPx2 73% 67%
Takacsi-Nagy et al.
[27] Stage III-IV 66 TPFx2, SRT+CPx3 vs. CRT 43% 41%
Ghi et al. [28] Stage III-IV 413 TPFx3, SRT+CPx2 vs.SRT+CTX 57.5% 47%
Our study Stage III-IV 47 TPFx3, SRT+CP weekly 61% 67%
TPF: docetaxel, cisplatin, 5-Fluorouracil; SRT: single daily fraction radiotherapy; HRT: hyperfractionated
radiotherapy; CBP: carboplatin; CP: cisplatin: CTX: cetuximab; CRT: chemoradiotherapy; 5-FU: 5-fluorouracil.
According to the survival data presented above, we suggest that 18F-FDG PET/CT scan obtained
after TPF-based ICT might be used for LA-SCCHN IMRT planning. Loco-regional failure analysis
also supports this approach. In our study 15 patients (31.9%) developed loco-regional disease
progression with a total of 32 progressive lesions. 8 lesions were in the primary tumor site and
24 in the regional lymphnode sites. 90.6% of progresses were in-field with highest levels localized
in high-to-intermediate risk volumes GTV70 (87.5%) and CTV60 (87.5%) and none in PTV50 volume.
For comparison, De Felice et al. presented the retrospective analysis of 56 patients who were diagnosed
with loco-regional progress of LA-SCCHN after ICT plus CRT [23]. In total 68 sites of progression were
analyzed, of them 35 were in primary tumor site and 33 in regional nodes. 95.6% of progressive lesions
were in-field, 82.9% in high-dose primary tumor CTV (GTV + 10 mm), and 72.7% in nodal high-dose
CTV. Similar results were demonstrated by Bayman et al. [29]. This study involved 136 patients with
carcinoma of the head and neck. 29 (21%) patients were treated with ICT plus CRT. 16 (12%) of patients
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progressed, all in high-dose regions. The main difference between the studies mentioned above and
our study is GTV to CTV margin. In both earlier studies CTV was defined as GTV plus 10 mm margin
and PTV–CTV plus 4 mm. In our study smaller 5 mm GTV to CTV margin and 3 mm CTV to PTV
margin (accounting for daily CBCT image guidance) was used. We want to point-out that despite the
smaller margins, results of loco-regional control were similar to previous studies, therefore we suggest
that 5 mm CTV and 3 mm PTV margins (with daily CBCT image guidance) might be considered for
18F-FDG PET/CT based IMRT planning after ICT for LA-SCCHN patients.
In recent years several authors demonstrated a prognostic value of 18F-FDG PET/CT metabolic
parameters in LA-SCCHN [15,16,30–32]. In publication by Paidpally et al. SUVmax, MTV and TLG were
proposed as non-invasive prognostic factors usable in management of LA-SCCHN [30]. These parameters
might be used for disease response evaluation, RT planning and follow-up. David et al. analyzed
74 LA-SCCHN patients with N2 or N3 nodal status [15]. SUVmax, SUVpeak (mean SUV within a 1-cm
sphere centered on SUVmax) of the primary tumor and LN were evaluated before and after treatment.
Neither initial nor post-treatment SUVmax and SUVpeak were associated with disease outcome. Choosing
the different approach and analyzing the dynamics of SUVmax (percentage decrease of the value after
ICT) on patient survival, we provide new evidence that the decrease of primary tumor SUVmax by
at least 74% and LN SUVmax by 68–69% may be used as independent LA-SCCHN prognostic factors.
However, our results contradict the results of Yu et al., who did not find an association between SUVmax
percentage decrease and LA-SCCHN patient survival [16].
Few authors also investigated the prognostic value of MTV and TLG. In the study of David et al.,
pre-treatment MTV value was linked with PFS and OS [15]. Yu et al. found that post-ICT MTV percentage
decrease by more than 42% and TLG by more than 55% significantly prolonged event-free survival [16].
In our study it was found that larger percentage decrease of MTV and TLG in primary tumor and
TLG in regional LN correlate with better 3-year PFS and OS rates, however different cut-off points
were established. MTV percentage decrease cut-off point for PFS prediction was 68%, for OS 69%.
Only primary tumor MTV decrease was significantly associated with disease outcome. As for TLG better
PFS was observed in patients with ≥76% primary tumor TLG decrease and ≥74% nodal TLG decrease
with similar results for OS ≥74% and ≥73% decrease respectively.
Limitations of this study include the usage of rigid image registration technique, which was used
for IMRT treatment planning and evaluation of recurrence patterns. There are no clear recommendations
in the literature regarding which image registration technique should be used for LA-SCHHN IMRT
planning. However, deformable registration seems to be a superior technique. Another limitation was
the lack of endoscopic tumor evaluation after ICT (21 out of 47 patients refused the second examination).
Due to this limitation, comparison of post-ICT residual primary tumor between PET/CT with objective
endoscopic evaluation method was not possible.
5. Conclusions
Results of this phase II cohort study demonstrate that post-ICT 18F-FDG PET/CT based RT planning
has no negative impact on loco-regional recurrence rates comparing with the patterns to pre-ICT
imaging-based treatment planning (demonstrated by others authors). Furthermore, we demonstrated
that SUVmax, MTV and TLG percentage decreases in primary tumors, and LN TLG decreases are
independent prognostic factors for PFS and OS in LA-SCCHN. In order to improve the analysis of
loco-regional progression and assess the future possibility of dose escalation in high-risk volumes, we are
initiating a 3D-printed phantom prototype filled with radiosensitive gels-based dosimetry for individual
patient dosimetry according to RT plans. Further prospective studies with larger sample sizes are
warranted to confirm the 18F-FDG-PET/CT based post-ICT target volume delineation technique before
its use in clinical practice. Also, we encourage larger validation studies of metabolic 18F-FDG-PET/CT
prognostic markers.
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